The Importance of Worsening Heart Failure in Ambulatory Patients: Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy

JACC: Heart Failure

Volumn 4, Issue 9, 2016, Pages 749-755

  Mallick, Aditi ^a   Gandhi, Parul U ^b   Gaggin, Hanna K ^a,c   Ibrahim, Nasrien ^a   Januzzi, James L ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

biomarkers; chronic heart failure; worsening heart failure

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; THIAZIDE DIURETIC AGENT; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGED; AMBULATORY MONITORING; ARTICLE; BODY MASS; BONE PLATING SYSTEM; CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; WORSENING HEART FAILURE; ACUTE DISEASE; AMBULATORY CARE; BLOOD; CARDIOVASCULAR DISEASE; DISEASE EXACERBATION; HEALTH CARE QUALITY; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PATIENT CARE PLANNING; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; AGED; AMBULATORY CARE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NATRIURETIC PEPTIDE, BRAIN; PATIENT CARE PLANNING; PEPTIDE FRAGMENTS; PROPORTIONAL HAZARDS MODELS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; STANDARD OF CARE; TREATMENT OUTCOME;

EID: 84966659087     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.03.012     Document Type: Article

References (17)

1. 1 Butler, J., Braunwald, E., Gheorghiade, M., Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. JAMA 312 (2014), 789–790.
2. 2 Dharmarajan, K., Hsieh, A.F., Kulkarni, V.T., et al. Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort study. BMJ, 350, 2015, h411.
3. 3 Setoguchi, S., Stevenson, L.W., Schneeweiss, S., Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 154 (2007), 260–266.
4. 4 Gaggin, H.K., Szymonifka, J., Bhardwaj, A., et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. J Am Coll Cardiol HF 2 (2014), 65–72.
5. 5 Januzzi, J.L., Rehman, S.U., Mohammed, A.A., et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 58 (2011), 1881–1889.
6. 6 Davison, B.A., Metra, M., Cotter, G., et al. Worsening heart failure following admission for acute heart failure: a pooled analysis of the PROTECT and RELAX-AHF Studies. J Am Coll Cardiol HF 3 (2015), 395–403.
7. 7 Gheorghiade, M., Greene, S.J., Butler, J., et al., SOCRATES-REDUCED Investigators and Coordinators. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA 314 (2015), 2251–2262.
8. 8 Moss, A.J., Hall, W.J., Cannom, D.S., et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361 (2009), 1329–1338.
9. 9 Bhardwaj, A., Rehman, S.U., Mohammed, A., Baggish, A.L., Moore, S.A., Januzzi, J.L., Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Am Heart J 159 (2010), 532–538.e1.
10. 10 Weiner, R.B., Baggish, A.L., Chen-Tournoux, A., et al. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. Eur J Heart Fail 15 (2013), 342–351.
11. 11 Gaggin, H.K., Motiwala, S., Bhardwaj, A., Parks, K.A., Januzzi, J.L., Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure. Circ Heart Fail 6 (2013), 1206–1213.
12. 12 Motiwala, S.R., Szymonifka, J., Belcher, A., et al. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail 15 (2013), 1157–1163.
13. 13 Allen, L.A., Spertus, J.A., End points for comparative effectiveness research in heart failure. Heart Fail Clin 9 (2013), 15–28.
14. 14 Bekelman, D.B., Plomondon, M.E., Carey, E.P., et al. Primary results of the Patient-Centered Disease Management (PCDM) for Heart Failure Study: a randomized clinical trial. JAMA Intern Med 175 (2015), 725–732.
15. 15 Sanada, S., Hakuno, D., Higgins, L.J., Schreiter, E.R., McKenzie, A.N., Lee, R.T., IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117 (2007), 1538–1549.
16. 16 Bhardwaj, A., Rehman, S.U., Mohammed, A.A., et al. Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Am Heart J 164 (2012), 793–799.e1.
17. 17 Gaggin, H.K., Truong, Q.A., Rehman, S.U., et al. Characterization and prediction of natriuretic peptide “nonresponse” during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study. Congest Heart Fail 19 (2013), 135–142.